

Article Information

Received date: Aug 24, 2017

Accepted date: Oct 07, 2017

Published date: Oct 17, 2017

***Corresponding author**

Jesús Morales Mazaa, Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Tel: +01 (55) 6165-0326; Email: medcardiouv@hotmail.com

Distributed under Creative Commons CC-BY 4.0

Keywords Chronic Pancreatitis; Treatment; Endoscopy; Surgery

Review Article

Chronic Pancreatitis: Current Concepts

Jesús Morales Maza*

Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Abstract

Chronic pancreatitis (CP) is an irreversible inflammatory process of the pancreas resulting in long-term severe abdominal pain and pancreatic exocrine and endocrine insufficiency. There are multiple causes of chronic pancreatitis, with alcohol being the most frequent. Computed tomography with contrast is the radiographic test of choice for diagnosis; frequent findings are calcifications. Treatment is based on changes in lifestyle followed by treatment with analgesics and pancreatic enzyme supplements. Endoscopic treatment is indicated for decompression of the pancreatic duct or treatment of complications of chronic pancreatitis. Several surgical techniques have been described whose main objective is to decompress the main pancreatic duct or to resect the inflammatory process that predominates in the head of the pancreas. Lateral pancreaticojejunostomy is the most commonly performed surgery in patients with chronic pancreatitis.

Incidence

Chronic Pancreatitis (CP) is an important cause of disabling pain that affects the quality of life of the patients [1]. Globally is the most frequent pancreatic pathology with a mortality of 0.09 deaths (95% CI 0.02-0.47) per 100 000 person-years for chronic pancreatitis [2]. It is estimated an overall incidence of 2 to 200 cases per 100,000 inhabitants per year and prevalence of 13 to 52 per 100,000 population [3]. In some regions there is a higher incidence as in India with an incidence of 114 to 200 per 100,000 inhabitants. The mean age of presentation is at 60 years of age [4,5].

Definition

CP has been defined as a continuing inflammatory disease of the pancreas, characterized by irreversible morphological change, and typically causing pain and permanent loss of function [6]. Progressively the endocrine and exocrine function is lost, generating chronic diarrhea and type 3c diabetes [7].

It is known that there is a genetic predisposition and multiple environmental factors.

The main symptom is pain that occurs in up to 90% of cases. It is also known that there is an increased risk of pancreatic cancer and inflammatory bowel disease [8-10]. CP occurs more frequently in men than in women [11].

Causes of Chronic Pancreatitis

The main cause of CP is alcohol [12]. Pathogenesis can be studied using the MANNHEIM classification (multiple (M) risk factor classification; alcohol consumption (A), nicotine consumption (N), nutritional factors (N), hereditary factors (H), efferent pancreatic duct factors (E), immunological factors (I), and various rare miscellaneous and metabolic (M) factors). This classification helps us to determine the main risk factors for CP and perform an earlier treatment [13,14].

Another frequently used classification is TIGAR-O (Toxic-metabolic, Idiopathic, Genetic, Autoimmune, Recurrent and severe acute pancreatitis, Obstructive) which is also based on the risk factors of CP [15].

Pathophysiology

To date there is still controversy about the mechanisms that contribute to the generation of pain in CP, it is known that pancreatic duct hypertension, pancreatic inflammation and peripancreatic infiltration by immune cells are the main mechanisms that could generate pain [16,17]. The most accepted theory was described by Whitcomb et al. The SAPE (Sentinel Acute Pancreatitis Event) hypothesis proposes a sentinel event of acute pancreatitis initiating the inflammatory process [18].

Several factors associated with CP have been described, including alcohol consumption (70% of cases), hereditary factors (the most important genetic factors are the mutations in the cationic trypsinogen PRSS1, the Serine Protease Inhibitor Type Kazal 1 (SPINK1) and carboxypeptidase A1, among others), hyperparathyroidism, hypertriglyceridemia, traumatism, some drugs such as valproate, azathioprine, statins, furosemide, interferon, steroids, cimetidine among others and some anatomic congenital abnormalities (pancreas divisum) [19-21].

OPEN ACCESS

Clinical Manifestations and Complications of Chronic Pancreatitis

Abdominal pain is the most frequent manifestation and multiple mechanisms of pain have been described [3]; alteration of the nervous conduction, alteration of the peripheral nociception, pancreatic neuropathy, mechanisms of central pain and alteration of the pancreatic duct pressure [22,23].

The pancreatic and peripancreatic inflammatory process generates multiple complications; endocrine insufficiency manifested with hyperglycemia and diabetes; exocrine pancreatic insufficiency manifested with chronic diarrhea; metabolic bone disease caused by sharing the same risk factors as osteopathy such as alcohol consumption, smoking, probable vitamin D insufficiency due to malabsorption [24] and chronic inflammation that favors the imbalance of bone production; increased risk of pancreatic cancer; presence of pseudocysts, duodenal and biliary obstruction, and splenic vein thrombosis [25].

It would seem that there are some risk factors for developing diabetes in patients with CP such as male sex, alcohol abuse despite knowing the diagnosis and some surgical procedures such as distal pancreatectomy [26].

It is recommended to perform an annual glucose tolerance test to identify any deterioration in glucose levels that may be problematic [27].

Diagnostic Evaluation

Diagnosis can be difficult in the early stages of the disease since patients may present typical clinical manifestations but minimal histological changes and normal findings in imaging studies [28] (Table 1).

Computed Tomography (CT) is considered the first approach study to rule out or confirm CP. Pancreatic calcifications are frequently observed in imaging studies such as CT, mainly in patients in whom the etiology is alcohol (20-40%), and has a sensitivity and specificity of 75% to 90% and 85%, respectively [29,30].

Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP), Magnetic Resonance Image (MRI) and CT all have comparable high diagnostic accuracy in the initial diagnosis of CP and the choice of imaging can be made based on clinical considerations [31].

Magnetic Resonance Cholangiopancreatography (MRCP) is a useful tool to support the diagnosis of CP; the frequent findings are irregular dilatations of the Main Pancreatic Duct (MPD) and irregular dilatations of pancreatic duct branches of variable intensity with scattered distribution throughout the pancreas and has a sensitivity of 85% and specificity of 100% [30,32].

Table 1: Diagnostic evaluation.

Computed tomography	The most frequent findings are pancreatic calcifications. Sensitivity: 75%-90%, specificity: 85%
Magnetic resonance cholangiopancreatography	The frequent findings are irregular dilatation of the Main Pancreatic Duct (MPD) and irregular dilatation of pancreatic duct branches. Sensitivity: 85%, specificity: 100%
Endoscopic ultrasound	Sensitivity: 97%, specificity: 60%
Endoscopic Retrograde Cholangiopancreatography (ERCP)	Findings: irregular dilatation of the MPD and irregular dilatation of pancreatic duct branches

On the other hand, it has been attempted to correlate the number of EUS pancreatic duct and parenchymal abnormalities, presence of calcification, and smoking or alcohol status, finding a good correlation with the diagnosis of pancreatic insufficiency the more alterations are found and presents a sensitivity and specificity of 97% and 60% respectively [30,33].

ERCP findings are also irregular dilatation of the MPD and irregular dilatation of pancreatic duct branches of variable intensity with scattered distribution throughout the entire pancreas [32].

The role of abdominal ultrasound has not been fully defined; it seems that this noninvasive tool has a good diagnostic result correlated with pancreatic insufficiency [34].

The early diagnosis of CP is difficult because of the lack of clinical and imaging manifestations so that recent miRNA serum markers have been studied to try to diagnose CP earlier and seem to have the potential to be applied clinically for early diagnosis of CP. These serum biomarkers studied are Hsa-miR-221 and hsa-miR-130a [35].

Pancreatic Function Tests

Pancreatic function tests are not diagnostic tests; are used to determine if there is functional complication from CP and are not performed routinely.

Some tests have been described such as the determination of fecal elastase-1 for the early detection of exocrine pancreatic insufficiency mainly in patients who have diarrhea and characteristic chronic abdominal pain [36].

Another diagnostic test of exocrine pancreatic insufficiency is 13C-Mixed Triglyceride Breath Test (TGBT) that assesses fat digestion and absorption and has been suggested as an alternative test to fecal elastase-1, however it is more expensive and shows the same results in diagnosis with a sensitivity of 81%, specificity 94%, Positive Predictive Value (PPV) 86% and Negative Predictive Value (NPV) 92% [37].

Secretin stimulation (SPFT) is a test in which secretin with or without Cholecystokinin (CCK) is administered and a sample of duodenum fluid is taken by endoscopy; this test is considered positive if low bicarbonate is found (peak concentration <75 mEq / L). This is the best test to diagnose exocrine pancreatic insufficiency with a sensitivity of the SPFT in diagnosing CP of 82%, specificity of 86%, PPV of 45% and NPV of 97% [38].

Other tests described to assess pancreatic function are fecal fat estimation, high acid steatocrit on spot stool, and low serum trypsinogen.

Pain Treatment

First-line medical options include the administration of pain medication, adjunctive agents and pancreatic enzymes, and abstinence

from alcohol and tobacco [39]. This conservative treatment is the basis of any adequate management of CP [40] (Table 2).

The first proposed step in the pharmacological treatment of pain is acetaminophen, but even the use of opioids has been suggested such as morphine [41].

The treatment of exocrine pancreatic insufficiency has been performed with Pancreatic Enzyme Replacement Therapy (PERT) and seems to improve nutritional serum parameters, improves pain and quality of life of patients although studies are lacking to determine the optimal regimen of treatment [42].

It has been proposed the use of micronutrients with antioxidants to treat CP but there seems to be no effect of intervention on outcome [43].

Some other therapies have been described as acupuncture with short-term pain control but without sufficient evidence yet to be routinely used [44].

Treatment with pancreatic enzymes

Although some individual studies reported a beneficial effect of pancreatic enzyme over placebo in improving pain control, decreasing the incidence of steatorrhea and decreasing analgesic consumption, the role of pancreatic enzymes for abdominal pain, weight loss, steatorrhea, analgesic use and quality of life in patients with CP remains equivocal [45]. As an enzyme replacement treatment, the dose of 90,000 units of lipase per capsule with food is suggested [46].

Indication of invasive treatment with endoscopy or surgery

The main indication for invasive treatment is intractable abdominal pain and treatment of complications already mentioned including suspected malignancy [47] (Table 3).

Endoscopic treatment

Pain can be treated by endoscopic treatment with good long-term results; this therapeutic maneuver has been used over 25 years. Some authors suggest that it should be considered as the initial treatment of choice in patients with dilated duct chronic pancreatitis, and continuous pain [48-51] Long-term pain control ranges from 50% to 77% among multiple series [52-55].

Although some randomized studies have been conducted to compare endoscopic versus surgical treatment where a better long-term pain relief was demonstrated with surgery and half of patients undergoing endoscopic treatment required surgical treatment, endoscopic treatment offers good long-term pain control results without the disadvantage of invasiveness [56,57].

Table 2: Conservative management in chronic pancreatitis.

Treatment of the cause	Alcoholism, smoking
Treatment of chronic pain	Analgesia based on WHO pain scale
Treatment of exocrine pancreatic insufficiency	Treatment with pancreatic enzymes
Treatment of endocrine pancreatic insufficiency	Diet, oral antidiabetic, insulin
Adjuvant therapy	Antioxidants

Multiple endoscopic techniques have been described; the Extracorporeal Shockwave Lithotripsy (ESWL) in combination with interventional endoscopy achieves reduction of pain in 45% to 76% of patients, [58-60] sphincterotomy, stone extraction and stent placement [61].

Other indications for endoscopic treatment are some complications of CP such as pancreatic pseudocysts and biliary obstructions [62].

Endoscopic Retrograde Pancreatography (ERP) is effective as a monotherapy and can be used to remove stones from the MPD [63]. Recently it has been used pancreatoscopy plus Electrohydraulic Lithotripsy (EHL) for pancreatic duct stones extraction using Spyglass [64].

There are some good response predictors to endoscopic treatment such as stones less than 10 mm in size located in the head and body of pancreas, when they are less than 3 stones without evidence of multiple stenosis [65]. On the other hand, some types of CP do not benefit from endoscopic treatment and it has been suggested that they should go on to surgery such as distal obstructions, presence of multiple pancreatic calcifications or the presence of inflammatory mass.

Some complications of stent placement within the pancreatic duct are stent fragmentation, which occurs in about 5% of cases [66]. Another complication that may occur is post-ERCP pancreatitis with similar incidence as in patients who do not have CP [67].

Surgical Techniques

Surgical procedures provide long-term pain relief, a good postoperative quality of life [68]. It has been demonstrated to be more effective than endoscopy in patients with pancreatic duct obstruction [69].

Many surgical treatment options have been described with good long-term results [70] ranging from highly invasive procedures such as total pancreatectomy and pancreatoduodenectomy [71] to more conservative procedures such as lateral pancreaticojejunostomy (Puestow procedure) and duodenum preserving pancreatic head resection such as the Frey, Beger, and Hamburg procedures [72-76]. It appears that pancreatic head resection procedures offer the best results with good safety of surgery [77]. Despite the many surgical techniques described, there is still no consensus on which surgery to perform [78].

Another procedure to treat CP is total pancreatectomy with islet autotransplantation; this procedure seeks to prevent the use of insulin so its main indication is when patients have not yet developed endocrine pancreatic insufficiency. The technique includes the preservation of the gland with culture of pancreatic cells and the infusion of these into the portal vein. It takes 300,000 to 400,000 islets

Table 3: Indications for surgical treatment.

Failure in conservative or endoscopic treatment
Intractable pain
Local symptomatic complications
Suspicion of malignancy

to successfully graft. The amount of islets that are usually obtained depends on the degree of disease present. Unfortunately, 25% to 30% of patients with CP are diabetic and therefore are not considered candidates for this procedure [79]. And like most of the previously mentioned procedures, it is already done by minimally invasive surgery with laparoscopy [80].

Some authors have suggested performing early surgery to prevent endocrine and exocrine failure [81,82] although evidence is lacking to define this behavior [83]. It should be borne in mind that although the pain decreases with surgery due to the reduction of ductal hypertension, the cellular damage continues and that is

why analgesic pain treatment is still required with enzymatic replacement, in addition to the discharge these patients require a nutritional plan and close postoperative monitoring [84,85].

Conclusions

CP is an irreversible inflammatory process of the pancreas. Diagnosis and therapeutic approach is complex because of the many tools we currently have and multiple treatment options. It is expected that the better understanding of the pathophysiology will improve the prognosis of these patients.

References

- Machicado JD, Amann ST, Anderson MA, Abberbock J, Sherman S, Conwell DL, et al. Quality of Life in Chronic Pancreatitis is Determined by Constant Pain, Disability/Unemployment, Current Smoking, and Associated Comorbidities. *Am J Gastroenterol*. 2017; 112: 633-642.
- Xiao AY, Tan ML, Wu LM, Asrani VM, Windsor JA, Yadav D, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. *Lancet Gastroenterol Hepatol*. 2016; 1: 45-55.
- Lévy P, Domínguez-Muñoz E, Imrie C, Löhr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. *United European Gastroenterol J*. 2014; 2: 345-354.
- Machicado JD, Yadav D. Epidemiology of Recurrent Acute and Chronic Pancreatitis: Similarities and Differences. *Dig Dis Sci*. 2017; 62: 1683-1691.
- Masamune A, Kikuta K, Nabeshima T, Nakano E, Hirota M, Kanno A, et al. Nationwide epidemiological survey of early chronic pancreatitis in Japan. *J Gastroenterol*. 2017; 52: 992-1000.
- Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. *Pancreatol*. 2016; 16: 218-224.
- Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. *Lancet Gastroenterol Hepatol*. 2016; 1: 226-237.
- Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. *Lancet*. 2011; 377: 1184-1197.
- Ueda J, Tanaka M, Ohtsuka T, Tokunaga S, Shimosegawa T. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. *Surgery*. 2013; 153: 357-364.
- Chen YL, Hsu CW, Cheng CC, Yang GT, Lin CS, Lin CL, et al. Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis: a nationwide population-based cohort study. *Curr Med Res Opin*. 2017; 33: 1077-1082.
- Coté GA, Yadav D, Slivka A, Hawes RH, Anderson MA, Burton FR, et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2011; 9: 266-273.
- Liao Z, Jin G, Cai D. Guidelines: diagnosis and therapy for chronic pancreatitis. *J Interv Gastroenterol*. 2013; 3: 133-136.
- Brock C, Nielsen LM, Lelic D, Drewes AM. Pathophysiology of chronic pancreatitis. *World J Gastroenterol*. 2013; 19: 7231-7240.
- He YX, Xu HW, Sun XT, Ye Z, Wang W, Lai XW, et al. Endoscopic management of early-stage chronic pancreatitis based on M-ANNHEIM classification system: a prospective study. *Pancreas*. 2014; 43: 829-833.
- Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. *Gastroenterology*. 2001; 120: 682-707.
- Friess H, Berberat PO, Wirtz M, Büchler MW. Surgical treatment and long-term follow-up in chronic pancreatitis. *Eur J Gastroenterol Hepatol*. 2002; 14: 971-7.
- Qingqiang Ni, Lin Yun, Manish Roy, Dong Shang. Advances in surgical treatment of chronic pancreatitis. *World J Surg Oncol*. 2015; 13: 34.
- Whitcomb DC. Hereditary pancreatitis: new insights into acute and chronic pancreatitis. *Gut*. 1999; 45: 317-322.
- Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortelet KJ, et al. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. *Pancreas*. 2014; 43: 1143-1162.
- Löhr JM, Domínguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). *United European Gastroenterol J*. 2017; 5: 153-199.
- Zator Z, Whitcomb DC. Insights into the genetic risk factors for the development of pancreatic disease. *Therap Adv Gastroenterol*. 2017; 10: 323-336.
- Poulsen JL, Olesen SS, Malver LP, Frøkjær JB, Drewes AM. Pain and chronic pancreatitis: A complex interplay of multiple mechanisms. *World J Gastroenterol*. 2013; 19: 7282-7291.
- Pasricha PJ. Unraveling the mystery of pain in chronic pancreatitis. *Nat Rev Gastroenterol Hepatol*. 2012; 9: 140-151.
- Olesen SS, Poulsen JL, Vestergaard P, Drewes AM. Vitamin-D deficiency in patients with chronic pancreatitis - Prevalence and pitfalls. *Pancreatol*. 2017; 17: 22-23.
- Ramsey ML, Conwell DL, Hart PA. Complications of Chronic Pancreatitis. *Dig Dis Sci*. 2017; 62: 1745-1750.
- Pan J, Xin L, Wang D, Liao Z, Lin JH, Li BR, et al. Risk Factors for Diabetes Mellitus in Chronic Pancreatitis: A Cohort of 2011 Patients. *Medicine (Baltimore)*. 2016; 95: e3251.
- Johnstone CC. An overview of the management of patients with chronic pancreatitis. *Nurs Stand*. 2016; 31: 54-63.
- Anaizi A, Hart PA, Conwell DL. Diagnosing Chronic Pancreatitis. *Dig Dis Sci*. 2017; 62: 1713-1720.
- Javadi S, Menias CO, Korivi BR, Shaaban AM, Patnana M, Alhalabi K, et al. Pancreatic Calcifications and Calcified Pancreatic Masses: Pattern Recognition Approach on CT. *AJR Am J Roentgenol*. 2017; 209: 77-87.
- Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. *Am Fam Physician*. 2007; 76: 1679-1688.
- Issa Y, Kempeneers MA, van Santvoort HC, Bollen TL, Bipat S, Boermeester MA. Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. *Eur Radiol*. 2017; 27: 3820-3844.
- Shimosegawa T, Kataoka K, Kamisawa T, Miyakawa H, Ohara H, Ito T, et al. The revised Japanese clinical diagnostic criteria for chronic pancreatitis. *J Gastroenterol*. 2010; 45: 584-591.
- Lee LS, Tabak YP, Kadiyala V, Sun X, Suleiman S, Johannes RS, et al. Diagnosis of Chronic Pancreatitis Incorporating Endosonographic Features, Demographics, and Behavioral Risk. *Pancreas*. 2017; 46: 405-409.

34. Engjom T, Sangnes DA, Havre RF, Erchinger F, Pham KD, Haldorsen IS, et al. Diagnostic Accuracy of Transabdominal Ultrasound in Chronic Pancreatitis. *Ultrasound Med Biol*. 2017; 43: 735-743.
35. Xin L, Gao J, Wang D, Lin JH, Liao Z, Ji JT, et al. Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis. *Sci Rep*. 2017; 7: 40019.
36. Domínguez-Muñoz JE, D Hardt P, Lerch MM, Löhr MJ. Potential for Screening for Pancreatic Exocrine Insufficiency Using the Fecal Elastase-1 Test. *Dig Dis Sci*. 2017; 62:1119-1130.
37. González-Sánchez V, Amrani R, González V, Trigo C, Picó A, de-Madaria E. Diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis: 13C-Mixed Triglyceride Breath Test versus Fecal Elastase. *Pancreatol*. 2017; 17: 580-585.
38. Ketwaroo G, Brown A, Young B, Kheraj R, Sawhney M, Morteale KJ, et al. Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis. *Am J Gastroenterol*. 2013; 108:1360-1376.
39. JGD'Haese, GO Ceyhan, IE Demir, E Tieftrunk, H Friess. Treatment options in painful chronic pancreatitis: a systematic review. *HPB (Oxford)*. 2014; 16: 512-521.
40. Strobel O, Büchler MW, Werner J. Surgical therapy of chronic pancreatitis: indications, techniques and results. *Int J Surg*. 2009; 7: 305-312.
41. de-Madaria E, Abad-González A, Aparicio JR, Aparisi L, Boadas J, Boix E, et al. The Spanish Pancreatic Club's recommendations for the diagnosis and treatment of chronic pancreatitis: Part 2 (treatment). *Pancreatol*. 2013; 13: 18-28
42. de la Iglesia-García D, Huang W, Szatmary P, Baston-Rey I, Gonzalez-Lopez J, Prada-Ramallal G, et al. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. *Gut*. 2016; 66:1354-1355.
43. Rupasinghe SN, Siriwardena AK. Long-term outcome of patients with chronic pancreatitis treated with micronutrient antioxidant therapy. *Hepatobiliary Pancreat Dis Int*. 2017; 16: 209-214.
44. Juel J, Liguori S, Liguori A, Poulsen JL, Valeriani M, Graversen C, et al. Acupuncture for Pain in Chronic Pancreatitis: A Single-Blinded Randomized Crossover Trial. *Pancreas*. 2017; 46:170-176.
45. Shafiq N, Rana S, Bhasin D, Pandhi P, Srivastava P, Sehmy SS, et al. Pancreatic enzymes for chronic pancreatitis. *Cochrane Database Syst Rev*. 2009; 4: CD006302.
46. DiMagno MJ, DiMagno EP. Chronic pancreatitis. *Curr Opin Gastroenterol*. 2014; 30: 500-506.
47. Dua MM, Visser BC. Surgical Approaches to Chronic Pancreatitis: Indications and Techniques. *Dig Dis Sci*. 2017; 62:1738-1744.
48. Clarke B, Slivka A, Tomizawa Y, Sanders M, Papachristou GI, Whitcomb DC, et al. Endoscopic therapy is effective for patients with chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2012; 10: 795-802.
49. Gabbrielli A, Mutignani M, Pandolfi M, Perri V, Costamagna G. Endotherapy of early onset idiopathic chronic pancreatitis: results with long-term follow-up. *Gastrointest Endosc*. 2002; 55: 488-493.
50. Gabbrielli A, Pandolfi M, Mutignani M, Spada C, Perri V, Petruzzello L, et al. Efficacy of main pancreatic-duct endoscopic drainage in patients with chronic pancreatitis, continuous pain, and dilated duct. *Gastrointest Endosc*. 2005; 61: 576-581.
51. Tringali A, Boskoski I, Costamagna G. The role of endoscopy in the therapy of chronic pancreatitis. *Best Pract Res Clin Gastroenterol*. 2008; 22: 145-165.
52. Jabłońska B. Is endoscopic therapy the treatment of choice in all patients with chronic pancreatitis? *World J Gastroenterol*. 2013; 19: 12-16.
53. Seicean A, Vultur S. Endoscopic therapy in chronic pancreatitis: current perspectives. *Clin Exp Gastroenterol*. 2014; 8: 1-11.
54. Weber A, Schneider J, Neu B, Meining A, Born P, von Delius S, et al. Endoscopic stent therapy in patients with chronic pancreatitis: A 5-year follow-up study. *World J Gastroenterol*. 2013; 19: 715-720
55. Okolo PI 3rd, Pasricha PJ, Kalloo AN. What are the long-term results of endoscopic pancreatic sphincterotomy?. *Gastrointest Endosc*. 2000; 52:15-19.
56. Cahen DL, Gouma DJ, Nio Y, Rauws EA, Boermeester MA, Busch OR, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. *N Engl J Med*. 2007; 356: 676-684.
57. Cahen DL, Gouma DJ, Laramée P, Nio Y, Rauws EA, Boermeester MA, et al. Long-term outcomes of endoscopic vs surgical drainage of the pancreatic duct in patients with chronic pancreatitis. *Gastroenterology*. 2011; 141:1690-1695.
58. Brand B, Kahl M, Sidhu S, Nam VC, Sriram PV, Jaeckle S, et al. Prospective evaluation of morphology, function, and quality of life after extracorporeal shockwave lithotripsy and endoscopic treatment of chronic calcific pancreatitis. *Am J Gastroenterol*. 2000; 95: 3428-3438.
59. Adamek HE, Jakobs R, Buttman A, Adamek MU, Schneider AR, Riemann JF. Long term follow up of patients with chronic pancreatitis and pancreatic stones treated with extracorporeal shock wave lithotripsy. *Gut*. 1999; 45: 402-405.
60. Bhasin DK, Poddar U. Long term follow up of patients with chronic pancreatitis and pancreatic stones treated with extracorporeal shock wave lithotripsy. *Gastrointest Endosc*. 2000; 52: 586-587.
61. Maydeo A, Dhir V. Focusing on the role of endoscopy in chronic pancreatitis management - taking nature's help. *Endoscopy*. 2017; 49: 317-318.
62. Dumonceau JM, Macias-Gomez C. Endoscopic management of complications of chronic pancreatitis. *World J Gastroenterol*. 2013; 19: 7308-7315.
63. Adler JM, Gardner TB. Endoscopic Therapies for Chronic Pancreatitis. *Dig Dis Sci*. 2017; 62:1729-1737.
64. Bekkali NL, Murray S, Johnson GJ, Bandula S, Amin Z, Chapman MH, et al. Pancreatoscopy-Directed Electrohydraulic Lithotripsy for Pancreatic Ductal Stones in Painful Chronic Pancreatitis Using SpyGlass. *Pancreas*. 2017; 46: 528-530.
65. Kahl S, Zimmermann S, Genz I, Glasbrenner B, Pross M, Schulz HU, et al. Risk factors for failure of endoscopic stenting of biliary strictures in chronic pancreatitis: a prospective follow-up study. *Am J Gastroenterol*. 2003; 98: 2448-2453.
66. Jagielski M, Smoczyński M, Jabłońska A, Adrych K. Endoscopic treatment of intraductal pancreatic stent fragmentation. *Dig Endosc*. 2017.
67. Zhao ZH, Hu LH, Ren HB, Zhao AJ, Qian YY, Sun XT, et al. Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis. *Gastrointest Endosc*. 2017.
68. Gourgiotis S, Dimopoulos N, Germanos S, Vougas V, Alfaras P, Hadjiyannakis E. Surgical management of chronic pancreatitis. *Hepatobiliary Pancreat Dis Int*. 2007; 6:121-133.
69. King JC, Abeywardina S, Farrell JJ, Reber HA, Hines OJ. A modern review of the operative management of chronic pancreatitis. *Am Surg*. 2010; 76: 1071-1074.
70. Lü WP, Shi Q, Zhang WZ, Cai SW, Jiang K, Dong JH. A meta-analysis of the long-term effects of chronic pancreatitis surgical treatments: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy. *Chin Med J (Engl)*. 2013; 126: 147-153.
71. Jimenez RE, Fernandez-del Castillo C, Rattner DW, Chang Y, Warshaw AL. Outcome of pancreaticoduodenectomy with pylorus preservation or with antrectomy in the treatment of chronic pancreatitis. *Ann Surg*. 2000; 231: 293-300.
72. Adams DB. The Puestow procedure: how I do it. *J Gastrointest Surg*. 2013; 17: 1138-1142.

73. Behrman SW, Mulloy M. Total pancreatectomy for the treatment of chronic pancreatitis: indications, outcomes, and recommendations. *Am Surg.* 2006; 72:297-302.
74. Bachmann K, Tomkoetter L, Erbes J, Hofmann B, Reeh M, Perez D, et al. Beger and Frey Procedures for Treatment of Chronic Pancreatitis: Comparison of Outcomes at 16-Year Follow-Up. *J Am Coll Surg.* 2014; 219: 208-216.
75. Kutup A, Vashist Y, Kaifi JT, Yekebas EF, Izbicki JR. For which type of chronic pancreatitis is the "Hamburg procedure" indicated? *J Hepatobiliary Pancreat Sci.* 2010; 17: 758-762.
76. Roch A, Teysseidou J, Mutter D, Marescaux J, Pessaix P. Chronic pancreatitis: A surgical disease? Role of the Frey procedure. *World J Gastrointest Surg.* 2014; 6: 129-135.
77. Andersen DK, Frey CF. The Evolution of the Surgical Treatment of Chronic Pancreatitis. *Ann. Surg.* 2010; 251: 18-32.
78. Vasile D, Ilco A, Popa D, Belega A, Pana S. The surgical treatment of chronic pancreatitis: a clinical series of 17 cases. *Chirurgia (Bucur).* 2013; 108: 794-799.
79. Hartmann D, Friess H. Surgical Approaches to Chronic Pancreatitis. *Gastroenterol Res Pract.* 2015; 2015:503109.
80. Fan CJ, Hirose K, Walsh CM, Quartuccio M, Desai NM, Singh VK, et al. Laparoscopic Total Pancreatectomy With Islet Autotransplantation and Intraoperative Islet Separation as a Treatment for Patients With Chronic Pancreatitis. *JAMA Surg.* 2017; 152: 550-556.
81. Yang CJ, Bliss LA, Schapira EF, Freedman SD, Ng SC, Windsor JA, et al. Systematic review of early surgery for chronic pancreatitis: impact on pain, pancreatic function, and re-intervention. *J Gastrointest Surg.* 2014; 18: 1863-1869.
82. Nealon WH, Thompson JC. Progressive loss of pancreatic function in chronic pancreatitis is delayed by main pancreatic duct decompression. A longitudinal prospective analysis of the modified puestow procedure. *Ann Surg.* 1993; 217: 458-466.
83. Ahmed Ali U, Issa Y, Bruno MJ, van Goor H, van Santvoort H, Busch OR, et al. Early surgery versus optimal current step-up practice for chronic pancreatitis (ESCAPE): design and rationale of a randomized trial. *BMC Gastroenterol.* 2013; 13: 49.
84. Büchler MW, Warshaw AL. Resection versus drainage in treatment of chronic pancreatitis. *Gastroenterology.* 2008; 134: 1605-1607.
85. Fisher AV, Sutton JM, Wilson GC, Hanseman DJ, Abbott DE, Smith MT, et al. High readmission rates after surgery for chronic pancreatitis. *Surgery.* 2014; 156: 787-794.